At Reviva we are focused on developing a drug that targets both the serotonin and dopamine receptor signaling systems to more effectively treat schizophrenia and its comorbid symptoms.” ...

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

The U.S. Food and Drug Administration approved a new schizophrenia treatment ... first to target cholinergic receptors ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

“The end game is trying to relate [dopamine signaling] back to schizophrenia and other disorders with working memory impairment,” study coauthor Joshua Roffman of MGH and Harvard University told The ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator (PAM) – is designed to have limited effect on dopamine neurotransmission ... Scale (PANSS) of schizophrenia symptoms ...

The advantage of atypical agents for alleviating impaired cognitive function in schizophrenia may be related to actions on 5-HT receptors. 5-HT 1A receptors are one of the most promising targets ...

For around 70 years, the treatment of schizophrenia has relied almost entirely on drugs that block dopamine D2 receptors, but KarXT is one of a clutch of new therapies emerging from the pharma ...

Thus far, drugs for schizophrenia have worked by blocking dopamine – a neurotransmitter ... Cobenfy, however, targets a different family of receptors in the brain, known as muscarinic receptors.

Recent research published in The American Journal of Psychiatry showcases the use of Cambridge Cognition’s Cantab product in two phase 3 clinical trials involving patients with schizophrenia. Cobenfy, ...